Currently out of the existing stock ratings of Uy Ear, 28 are a HOLD (35%), 50 are a BUY (62.5%), 2 are a SELL (2.5%).

Uy Ear

Work Performance Price Targets & Ratings Chart

Analyst Uy Ear, currently employed at MIZUHO, carries an average stock price target met ratio of 40.79% that have a potential upside of 30.88% achieved within 190 days.

Uy Ear’s has documented 152 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on QURE, Uniqure NV at 14-Aug-2025.

Wall Street Analyst Uy Ear

Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 1/3/2024. The price target of $8 was fulfilled within 44 days with a profit of $4.09 (104.6%) receiving and performance score of 23.77.

Average potential price target upside

of $29.39 (26.77%) on SRPT (SAREPTA THERAPEUTICS).
of $10.37 (42.57%) on ALKS (ALKERMES PLC).
of $9.13 (8.53%) on NBIX (NEUROCRINE BIOSCIENCES).

ARQT Arcutis Biotherapeutics AVRO AVROBIO NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc EOLS Evolus OCGN Ocugen SELB Selecta Biosciences SRPT Sarepta Therapeutics RVNC Revance The QURE Uniqure NV SAGE Sage Therapeutic RLMD Relmada Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Serge Belanger (NEEDHAM)